

MicroRNA-133b inhibits the migration and invasion of non small cell lung cancer cells via targeting FSCN1

XUCHENG YANG^{1*}, PENGFEI LEI^{1*}, YONG HUANG², ZIJIAN ZHANG² and YINGYING ZHANG²

Departments of ¹Orthopedics and ²Oncology, Xiangya Hospital of Central South University, Changsha, Hunan 410008, P.R. China

Received March 22, 2015; Accepted April 13, 2016

DOI: 10.3892/ol.2016.5044

Abstract. MicroRNA (miR)-133b has been reported to act as a tumor suppressor in multiple types of human cancers, including non small cell lung cancer (NSCLC). However, the underlying mechanism by which miR-133b inhibits NSCLC metastasis remains largely unclear. In the present study, reverse transcription-quantitative polymerase chain reaction and western blotting were used to detect messenger RNA and protein expression. A wound healing assay and transwell assay were used to examine the cell migration and invasion. The expression level of miR-133b was found to be significantly downregulated in NSCLC cell lines compared with normal lung epithelial BEAS-2B cells. Further investigation identified fascin1 (FSCN1) as a direct target of miR-133b in NSCLC cells. The expression of FSCN1 was significantly increased in NSCLC cell lines compared with BEAS-2B cells, and its protein expression was negatively regulated by miR-133b in NSCLC A549 cells. Further investigation showed that the upregulation of miR-133b notably inhibited NSCLC cell migration and invasion, while the overexpression of FSCN1 significantly promoted NSCLC cell migration and invasion. Furthermore, the overexpression of FSCN1 reversed the suppressive effect of miR-133b overexpression on NSCLC cell migration and invasion. Accordingly, the present study suggests that miR-133b inhibits the migration and invasion of NSCLC cells via directly targeting FSCN1, and thus may be used for the treatment of NSCLC metastasis.

Introduction

As the leading cause of cancer-associated mortality, the incidence of lung cancer has been increasing worldwide (1).

Correspondence to: Dr Yingying Zhang, Department of Oncology, Xiangya Hospital of Central South University, 87 Xiangya Road, Changsha, Hunan 410008, P.R. China
E-mail: xiangyazyzy@163.com

*Contributed equally

Key words: non small cell lung cancer, microRNA-133b, fascin1, migration, invasion

Non small cell lung carcinoma (NSCLC) is the term given to any type of epithelial lung cancer that cannot be categorized as small cell lung carcinoma (SCLC), and the most common types include squamous cell carcinoma, large cell carcinoma and adenocarcinoma (2). Despite improvements in surgery, radiotherapy and chemotherapy, the overall 5-year survival rate remains poor, at <15% (1,3). As the deregulation of oncogenes or tumor suppressors has been implicated in the development and progression of NSCLC, investigations regarding the molecular targets show promise for the treatment of NSCLC (4,5).

MicroRNAs (miRs) are non-coding RNAs of 18-25 nucleotides in length that can result in the inhibition of gene expression at a post-transcriptional stage, through binding to the 3'-untranslational region (UTR) of messenger RNAs (mRNAs) (6). Previously, the deregulation of miRs has been reported to be associated with the development and advancement of NSCLC (7,8). Among these miRs, miR-133b has been indicated to inhibit NSCLC growth via targeting epidermal growth factor receptor, suggesting that miR-133b may be a tumor suppressor in NSCLC (9). However, the exact role of miR-133b in the regulation of NSCLC cell migration and invasion and the underlying mechanisms have not been previously elucidated.

Fascin1 (FSCN1) is a member of the FSCN family of actin-binding proteins, responsible for the organization of F-actin into parallel bundles, and participates in the formation of actin-based cellular projections (10). FSCN1 has been previously demonstrated to be associated with lymph node metastasis and tumor node metastasis (TNM) staging, but not tumor proliferation, in NSCLC, and to promote NSCLC A549 cell migration and invasion *in vitro* and *in vivo* (11). However, the regulatory mechanism of FSCN1 in NSCLC cell migration and invasion remains largely unknown.

The present study aimed to explore the molecular mechanisms by which miR-133b regulates the migration and invasion of NSCLC cells.

Materials and methods

Reagents. Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), Trizol reagent, MiRNA Reverse Transcription kit, SYBR Green RT-PCR kit, BCA Protein Assay kit, ECL Western Blotting kit, pMir-Report vector and

Lipofectamine 2000 were purchased from Thermo Fisher Scientific, Inc. (Waltham, MA, USA). The plasmid of FSCN1, scramble miRNA mimics, miR-133b mimics, miR-133b inhibitor and MiRNA Q-PCR Detection kit were purchased from GeneCopoeia (FulGen Co., Ltd., Guangzhou, China). The Stratagene QuikChange site-directed mutagenesis kit was purchased from Agilent Technologies, Inc. (Santa Clara, CA, USA). The pRL-SV40 vector was purchased from Promega Corporation (Madison, WI, USA). Mouse monoclonal anti-FSCN1 (dilution, 1:100; catalog no., ab49815) and mouse monoclonal anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH; dilution, 1:100; catalog no., ab8245) primary antibodies and rabbit anti-mouse polyclonal horseradish peroxidase-conjugated secondary antibodies (dilution, 1:20,000; catalog no., ab6728) were purchased from Abcam (Cambridge, MA, USA). The Cell Invasion Assay kit was purchased from Merck Millipore (Darmstadt, Germany).

Cell lines and cell culture. Five human NSCLC cell lines, H1229, A549, H358, H460 and SK-MES-1, and normal human lung epithelial BEAS-2B cells were purchased from the Cell Bank of Central South University (Changsha, China). All cells were cultured in DMEM supplemented with 10% FBS at 37°C in 5% CO₂.

RNA extraction and reverse transcription (RT)-quantitative polymerase chain reaction (qPCR). Total RNA was extracted using Trizol reagent, according to the manufacturer's instructions. For the detection of miR expression, the MiRNA Reverse Transcription kit was used to convert 10 ng of total RNA into complementary DNA (cDNA), according to the manufacturer's instructions. RT-qPCR was then performed using a miRNA Q-PCR Detection kit on an Applied Biosystems 7500 Real-time PCR System (Thermo Fisher Scientific, Inc.). The U6 gene was used as an internal reference. DNase I (1 unit) was used in the reaction. The expression of mRNA was detected by RT-qPCR using the SYBR Green RT-PCR kit, according to the manufacturer's instructions. The specific primer pairs were as follows: FSCN1, sense, 5'-ATTCTTGGA CCACAAGGGAATAC-3' and antisense, 5'-GCCATAAGA GCATAAGCCTCACA-3'; GAPDH (as an internal reference), sense, 5'-GGAGCGAGATCCCTCCAAAAT-3' and antisense, 5'-GGCTGTTGT CATACTTCTCATGG-3'. The relative mRNA expression was quantified using the GraphPad Prism 4.0 software (GraphPad Software, Inc., La Jolla, CA, USA) and 2^{-ΔΔC_q} method (12).

Western blotting. Cells were solubilized in cold radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology, Shanghai, China). Proteins were quantified using the BCA Assay kit and then separated with 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and transferred onto a polyvinylidene difluoride (PVDF) membrane (Thermo Fisher Scientific, Inc.), which was then incubated with Tris-buffered saline and Tween 20 (Beyotime Institute of Biotechnology) containing 5% milk at room temperature for 3 h. The PVDF membrane was then incubated with mouse anti-FSCN1 and mouse anti-GAPDH primary antibodies at room temperature for 3 h, and then rabbit anti-mouse secondary antibody at room temperature for 40 min. Chemiluminent

detection was performed using an ECL Western Blotting kit. The relative protein expression was analyzed by Image-Pro Plus software version 6.0 (Media Cybernetics, Inc., Rockville, MD, USA) and presented as the density ratio vs. GAPDH.

Transfection. Lipofectamine 2000 was used to perform transfection, according to the manufacturer's instructions. Briefly, plasmid or miRNA mimics and Lipofectamine 2000 were diluted with serum-free medium (DMEM), respectively. The diluted Lipofectamine 2000 was added into the diluted plasmid or miRNA mimics, incubated for 20 min at room temperature, and then added into the cell suspension. The cells were then incubated at 37°C in 5% CO₂ for 6 h. Following incubation, the medium in each well was replaced with DMEM supplemented with 10% FBS.

Dual luciferase reporter assays. A luciferase reporter assay was performed in order to clarify whether FSCN1 is a direct target gene of miR-133b in NSCLC cells. Total cDNA, obtained via the aforementioned RNA extraction and RT-qPCR method, from NSCLC A549 cells was used to amplify the 3'UTR of FSCN1, which was then cloned into a pMir-Report vector. Mutations were introduced within the potential seed sequences of the 3'UTR of FSCN1 using the QuikChange site-directed mutagenesis kit. Using Lipofectamine 2000, cells were transfected with the pMir-Report vectors, containing the wild type (WT) or mutant type (MUT) of FSCN1 3'UTR, and miR-133b mimics, respectively. The pRL-SV40 vector carrying the *Renilla* luciferase gene was used as an internal control. Luciferase activity was determined after 48 h, using the Dual-Glo substrate system and LD400 luminometer (Beckman Coulter, Inc., Brea, CA, USA). Data are presented as the ratio of *Renilla* luciferase to firefly luciferase.

Cell migration detection. A wound healing assay was performed in order to assess the cell migratory capacity of NSCLC A549 cells in 4 groups: Non transfected A549 cells were used as control; the miR-133b group contained A549 cells transfected with the miR-133b mimic; the FSCN1 group contained A549 cells transfected with the FSCN1 plasmid; and the miR-133b+FSCN1 group contained A549 cells co-transfected with the miR-133b mimic and FSCN1 plasmids. In brief, 1x10⁶ A549 cells were cultured to confluence in DMEM supplemented with 10% FBS at 37°C in 5% CO₂ for 24 h, until full confluence. Wounds of ~1 mm in length were created on the cells with a plastic scribe (BD Biosciences, Franklin Lakes, NJ, USA), and cells were washed with PBS for 5 min and incubated in DMEM at 37°C in 5% CO₂ for 24 h. Subsequent to wounding, cells were incubated in DMEM including 10% FBS. Following culture for 48 h, cells were observed under a microscope (SMZ1000; Nikon Corporation, Tokyo, Japan).

Cell invasion detection. Cells in each aforementioned group were starved in serum-free medium for 24 h, and then resuspended in serum-free medium. The cell suspension was added into the upper Transwell chamber (BD Biosciences), while the lower chamber was filled with DMEM containing 10% FBS. Following incubation for 24 h, cells attached to the bottom were stained with crystal violet (Beyotime Institute of




Figure 1. Reverse transcription-polymerase chain reaction was used to determine the expression level of miR-133b in four NSCLC cell lines, H1229, A549, H358, H460 and SK-MES-1, compared with a normal human lung epithelial cell line, BEAS-2B. *P<0.05 vs. BEAS-2B. **P<0.01 vs. BEAS-2B. miR, microRNA.




Figure 2. (A) Seed sequences for miR-133b at the WT or MT of FSCN1 3'UTR are shown. (B) Luciferase reporter assay was performed to confirm whether FSCN1 is a target gene of miR-133b. The luciferase activity was reduced only in NSCLC A549 cells co-transfected with miR-133b mimics and WT of FSCN1 3'UTR. However, in other groups, the luciferase activity was unchanged. **P<0.01 vs. Control. (C) Reverse transcription-polymerase chain reaction was used to determine the mRNA expression level of FSCN1 in four NSCLC cell lines, H1229, A549, H358, H460 and SK-MES-1, compared with normal human lung epithelial BEAS-2B cells. **P<0.01 vs. BEAS-2B. miR, microRNA; WT, wild type; MUT, mutant type; FSCN1, fascin1; UTR, untranslated region; NC, negative control; mRNA, messenger RNA.

Biotechnology) for 20 min, and then washed with PBS 3 times, each for 5 min, and dried in air. Invasive cells were observed under a microscope (SMZ1000; Nikon Corporation).

Statistical methods. Data were expressed as mean ± standard deviation of three independent experiments. Statistical analysis was performed by using SPSS 17.0 statistical software (SPSS, Chicago, IL, USA). The differences between groups were determined using the one-way analysis of variance. P<0.05 was considered to indicate a statistically significant difference.

Results

miR-133b is downregulated in NSCLC cell lines. RT-qPCR was first performed in order to determine the expression level of miR-133b in five human NSCLC cell lines, H1229, A549, H358, H460 and SK-MES-1, and in normal human lung epithelial BEAS-2B cells. As shown in Fig. 1, miR-133b was significantly downregulated in NSCLC cell lines compared to BEAS-2B cells. As A549 cells showed the most significant decrease in miR-133b expression (Fig. 1), this cell line was used in the following experiments.

FSCN1 is identified as a target gene of miR-133b in NSCLC cells. According to bioinformatical prediction, FSCN1 is a putative target gene of miR-133b (Fig. 2A). A luciferase

reporter assay was performed in order to clarify whether miR-133b can directly bind to seed sequences in the FSCN1 3'-UTR in NSCLC A549 cells. As shown in Fig. 2B, the luciferase activity was remarkably reduced in A549 cells co-transfected with the WT FSCN1 3'UTR and miR-133b mimics, but showed no difference in A549 cells co-transfected with the MUT FSCN1 3'UTR and miR-133b mimics (P>0.05), compared with the control group, indicating that FSCN1 is a target gene of miR-133b in NSCLC cells.

The expression level of FSCN1 was then determined by performing RT-qPCR on NSCLC cell lines, H1229, A549, H358, H460 and SK-MES-1, and normal human lung epithelial BEAS-2B cells. As shown in Fig. 2C, the mRNA levels of FSCN1 were significantly increased in NSCLC cell lines compared with normal human lung epithelial BEAS-2B cells, respectively.

miR-133b negatively regulates FSCN1 expression in NSCLC cells. As miRs generally inhibit the expression of their target genes at a post-transcriptional level (13), the present study further determined whether miR-133b negatively regulated the FSCN1 expression in NSCLC A549 cells. Following the transfection of NSCLC A549 cells with miR-133b mimics or inhibitor, the expression level of miR-133b was detected. As shown in Fig. 3A, transfection with miR-133b mimics significantly enhanced the expression level of miR-133b, while transfection with miR-133b




Figure 3. (A) Reverse transcription-quantitative polymerase chain reaction was used to determine the expression level of miR-133b in A549 cells transfected with miR-133b mimics or miR-133b inhibitor, respectively. (B) Western blot analysis was used to determine the protein expression level of FSCN1 in each group. GAPDH was used as an internal reference. Non-transfected A549 cells were used as control. ** $P < 0.01$ vs. Control. miR, microRNA; FSCN1, fascin1; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.




Figure 4. Wound healing assays were conducted to examine the cell migration capacities of A549 cells transfected with (A) miR-133b mimics and (B) FSCN1 plasmids. Transwell assays were conducted to examine the cell invasion capacities of A549 cells transfected with (C) miR-133b mimics and (D) FSCN1 plasmids. Non-transfected A549 cells were used as control. ** $P < 0.01$ vs. Control. miR, microRNA; FSCN1, fascin1.

inhibitor significantly inhibited its expression. The protein levels of FSCN1 were then determined by using western blot analysis. The data showed that the overexpression of miR-133b

suppressed the protein level of FSCN1, while silencing of miR-133b expression notably promoted the protein expression of FSCN1 in NSCLC A549 cells (Fig. 3B).




Figure 5. (A) Western blot analysis was conducted to determine the protein level of FSCN1 in A549 cells transfected with miR-133b mimics, or co-transfected with miR-133b mimics and FSCN1 plasmids, respectively. GAPDH was used as an internal reference. (B) A wound healing assay and (C) Transwell assay were conducted to examine the cell migration and invasion in each group. Non-transfected A549 cells were used as control. **P<0.01 vs. Control. miR, microRNA; FSCN1, fascin1; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

Roles of miR-133b and FSCN1 in the regulation of migration and invasion of NSCLC cells. The wound heal assay and Transwell assay were then performed to investigate the roles of FSCN1 and miR-133b in the regulation of migration and invasion of NSCLC A549 cells. As shown in Fig. 4A and B,

overexpression of miR-133b notably suppressed A549 cell migration and invasion. Furthermore, FSCN1 plasmids were transfected into A549 cells. As shown in Fig. 4C and D, the overexpression of FSCN1 notably enhanced A549 cell migration and invasion. Therefore, miR-133b and FSCN1 played contrary roles in the regulation of migration and invasion of NSCLC A549 cells.

Upregulation of FSCN1 reverses the inhibitory effect of miR-133b overexpression on NSCLC cell migration and invasion. The present study additionally investigated whether the role of miR-133b in the regulation of NSCLC cell migration and invasion was through the modulation of FSCN1. NSCLC A549 cells were transfected with miR-133b mimics, or co-transfected with miR-133b mimics and a FSCN1 plasmid. The protein level of FSCN1 in each group was then determined, which indicated that FSCN1 expression was increased in A549 cells co-transfected with miR-133b mimics and FSCN1 plasmids compared with A549 cells transfected with miR-133b mimics only (Fig. 5A). The overexpression of FSCN1 was also demonstrated to reverse the inhibitory effect of miR-133b upregulation on A549 cell migration and invasion (Fig. 5B and C). These findings suggest that miR-133b inhibits the migration and invasion of NSCLC A549 cells through targeting FSCN1.

Discussion

The present study showed that miR-133b was significantly downregulated in NSCLC cell lines compared with normal lung epithelial cells. Further investigation revealed that FSCN1, upregulated in NSCLC cell lines, was a direct target of miR-133b in NSCLC A549 cells, and that its protein expression was negatively regulated by miR-133b in NSCLC cells. Upregulation of miR-133b notably inhibited NSCLC cell migration and invasion, while the overexpression of FSCN1 significantly promoted NSCLC cell migration and invasion. Furthermore, overexpression of FSCN1 reversed the suppressive effect of miR-133b overexpression on NSCLC cell migration and invasion.

The deregulation of miRs has been demonstrated to be important for NSCLC growth and metastasis (14,15). For instance, low miR-145 and high miR-367 expression are associated with an unfavorable prognosis in patients with NSCLC (16). miR-145 can inhibit NSCLC cell proliferation by targeting v-myc avian myelocytomatosis viral oncogene homolog (17). In the present study, miR-133b was frequently downregulated in NSCLC cell lines compared with normal lung epithelial cells. It has been previously reported that miR-133b is significantly downregulated in lung tumor tissue compared with adjacent uninvolved tissue (18). In addition, miR-133b was indicated to be associated with tumor stage, the degree of regional lymph node involvement, visceral pleura or vessel invasion and epidermal growth factor receptor (EGFR) mRNA expression in Chinese patients with NSCLC (9). Accordingly, miR-133b may act as a tumor suppressor in NSCLC.

The regulatory mechanism of miR-133b in the regulation of human cancers including NSCLC has been widely studied (9,19,20). Crawford *et al* suggested that two members

of the B cell lymphoma-2 (BCL-2) family, myeloid cell leukemia 1 (MCL-1) and BCL-2 like 2, were targets of miR-133b, and that the overexpression of miR-133b induced apoptosis following exposure to gemcitabine in lung adenocarcinoma H2009 cells (18). In addition, EGFR was also found to be a target of miR-133b, and the overexpression of miR-133b was indicated to modulate apoptosis, invasion and sensitivity to EGFR-tyrosine kinase inhibitor therapy through the EGFR signaling pathways, particularly in EGFR-addicted NSCLC cells (9). Wu *et al* selected miR-133b as a therapeutic target for lung cancer, and found that lipoplexes delivered pre-miR-133b in a more efficient manner, with a ~2.3-fold increase in mature miR-133b expression and ~1.8-fold difference in MCL-1 protein downregulation *in vitro*, when compared with siPORT NeoFX transfection agent (21). In addition, mice treated with pre-miR-133b containing lipoplexes demonstrated mature miR-133b expression in the lungs that was ~52-fold higher compared with untreated mice (21). However, the exact role of miR-133b in mediating NSCLC cell migration and invasion and the detailed molecular mechanism, remains largely unknown.

In the present study, the overexpression of miR-133b notably inhibited NSCLC cell migration and invasion, suggesting that miR-133b suppress the regulation of NSCLC metastasis. Furthermore, FSCN1 was found to be a direct target of miR-133b in NSCLC cells, and was involved in miR-133b-mediated NSCLC cell migration and invasion. As a member of the FSCN family of actin-binding proteins, FSCN1 is responsible for organization of F-actin into parallel bundles and the formation of actin-based cellular protrusions (22). Therefore, FSCN1 is involved in the regulation of cell motility. In the present study, FSCN1 was notably upregulated in NSCLC cell lines, and the overexpression of FSCN1 reversed the suppressive effect of miR-133b overexpression on NSCLC cell migration and invasion, suggesting that FSCN1 plays an oncogenic role in NSCLC (23-25). Similar findings have also been reported in other types of human cancers; for instance, the knockdown of FSCN1 was found to inhibit the proliferation and invasion of gastric cancer cells (23). In addition, the inhibition of FSCN1 resulted in a reduced number of filopodia, an altered glioma cell shape, and inhibited the migration and invasion of glioma cells (24). FSCN1 was also found to be a promoter of breast cancer invasion via the modification of metastasis-associated molecules (25).

Previous studies have also reported that miR-133b negatively regulates the expression of FSCN1 in other types of human cancers, including esophageal squamous cell carcinoma (ESCC) and gastric cancer (23,26,27). Kano *et al* found that the overexpression of miR-133b inhibited ESCC cell proliferation and invasion, that FSCN1 was a target of miR-133b and that the knockdown of FSCN1 also suppressed ESCC cell proliferation and invasion (26). Yamamoto *et al* reported that FSCN1 was upregulated in association with miR-133b downregulation in high-grade gastrointestinal stromal tumors, and FSCN1 upregulation was significantly correlated with a shorter disease-free survival time and several aggressive pathological factors, which suggests that the downregulation of miR-133b and overexpression of FSCN1 may be important for the progression of gastrointestinal stromal tumor (27). The data in the present study expands the understanding of miR-133b and FSCN1 in human cancers.

In summary, the present study indicates that miR-133b suppresses the regulation of NSCLC cell migration and invasion via targeting FSCN1, suggesting that miR-133b may be used for the treatment of NSCLC.

References

- DeSantis C, Ma J, Bryan L and Jemal A: Breast cancer statistics, 2013. *CA Cancer J Clin* 64: 52-62, 2014.
- Dimou A and Papadimitrakopoulou V: Non-small cell lung cancer beyond biomarkers: The evolving landscape of clinical trial design. *J Pers Med* 4: 386-401, 2014.
- Chouaid C, Crequit P, Borget I and Vergnenegre A: Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: A systematic review. *Clinicoecon Outcomes Res* 7: 9-15, 2014.
- Landi L and Cappuzzo F: Pharmacotherapy targeting the EGFR oncogene in NSCLC. *Expert Opin Pharmacother* 15: 2293-2305, 2014.
- Domvri K, Zarogoulidis P, Darwiche K, Browning RF, Li Q, Turner JF, Kioumis I, Spyrtos D, Porpodis K, Papaiwannou A, *et al*: Molecular targeted drugs and biomarkers in NSCLC, the evolving role of individualized therapy. *J Cancer* 4: 736-754, 2013.
- Ambros V: The functions of animal microRNAs. *Nature* 431: 350-355, 2004.
- Li J, Song Y, Wang Y, Luo J and Yu W: MicroRNA-148a suppresses epithelial-to-mesenchymal transition by targeting ROCK1 in non-small cell lung cancer cells. *Mol Cell Biochem* 380: 277-282, 2013.
- Jiang M, Zhang P, Hu G, Xiao Z, Xu F, Zhong T, Huang F, Kuang H and Zhang W: Relative expressions of miR-205-5p, miR-205-3p and miR-21 in tissues and serum of non-small cell lung cancer patients. *Mol Cell Biochem* 383: 67-75, 2013.
- Liu L, Shao X, Gao W, Zhang Z, Liu P, Wang R, Huang P, Yin Y and Shu Y: MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor. *FEBS J* 279: 3800-3812, 2012.
- Zheng K, Liu W, Liu Y, Jiang C and Qian Q: MicroRNA-133a suppresses colorectal cancer cell invasion by targeting Fascin1. *Oncol Lett* 9: 869-874, 2015.
- Zhao J, Zhou Y, Zhang Z, Tian F, Ma N, Liu T, Gu Z and Wang Y: Upregulated fascin1 in non-small cell lung cancer promotes the migration and invasiveness, but not proliferation. *Cancer Lett* 290: 238-247, 2010.
- Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^{(-Delta Delta C(T))} Method. *Methods* 25: 402-408, 2001.
- Boon RA and Vickers KC: Intercellular transport of microRNAs. *Arterioscler Thromb Vasc Biol* 33: 186-192, 2013.
- Liu X, Yan S, Pei C and Cui Y: Decreased microRNA-132 and its function in human non-small cell lung cancer. *Mol Med Rep* 11: 3601-3608, 2015.
- Liu MX, Zhou KC and Cao Y: MCRS1 overexpression, which is specifically inhibited by miR-129*, promotes the epithelial-mesenchymal transition and metastasis in non-small cell lung cancer. *Mol Cancer* 13: 245, 2014.
- Campayo M, Navarro A, Vinolas N, Diaz T, Tejero R, Gimferrer JM, Molins L, Cabanas ML, Ramirez J, Monzo M and Marrades R: Low miR-145 and high miR-367 are associated with unfavourable prognosis in resected nonsmall cell lung cancer. *Eur Respir J* 41: 1172-1178, 2013.
- Chen Z, Zeng H, Guo Y, Liu P, Pan H, Deng A and Hu J: MiRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. *J Exp Clin Cancer Res* 29: 151, 2010.
- Crawford M, Batte K, Yu L, Wu X, Nuovo GJ, Marsh CB, Otterson GA and Nana-Sinkam SP: MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. *Biochem Biophys Res Commun* 388: 483-489, 2009.
- Chen XN, Wang KF, Xu ZQ, Li SJ, Liu Q, Fu DH, Wang X and Wu B: MiR-133b regulates bladder cancer cell proliferation and apoptosis by targeting Bcl-w and Akt1. *Cancer Cell Int* 14: 70, 2014.
- Wang J, Li Y and Jiang C: MiR-133b contributes to arsenic-induced apoptosis in U251 glioma cells by targeting the hERG channel. *J Mol Neurosci* 55: 985-994, 2015.

21. Wu Y, Crawford M, Yu B, Mao Y, Nana-Sinkam SP and Lee LJ: MicroRNA delivery by cationic lipoplexes for lung cancer therapy. *Mol Pharm* 8: 1381-1389, 2011.
22. Park SH, Song JY, Kim YK, Heo JH, Kang H, Kim G, An HJ and Kim TH: Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells. *Int J Oncol* 44: 637-646, 2014.
23. Guo L, Bai H, Zou D, Hong T, Liu J, Huang J, He P, Zhou Q and He J: The role of microRNA-133b and its target gene FSCN1 in gastric cancer. *J Exp Clin Cancer Res* 33: 99, 2014.
24. Hwang JH, Smith CA, Salhia B and Rutka JT: The role of fascin in the migration and invasiveness of malignant glioma cells. *Neoplasia* 10: 149-159, 2008.
25. Al-Alwan M, Olabi S, Ghebeh H, Barhoush E, Tulbah A, Al-Tweigeri T, Ajarim D and Adra C: Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules. *PLoS One* 6: e27339, 2011.
26. Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M and Matsubara H: MiR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. *Int J Cancer* 127: 2804-2814, 2010.
27. Yamamoto H, Kohashi K, Fujita A and Oda Y: Fascin-1 overexpression and miR-133b downregulation in the progression of gastrointestinal stromal tumor. *Mod Pathol* 26: 563-571, 2013.

RETRACTED